COLI’s Results Disappoint, but Earnings Should See Swift Recovery
No-moat China Overseas Land & Investment 00688 reported weak 2022 numbers with revenue dropping 26% year on year and net profit down 43%. However, we expect around 11% year-on-year growth in 2023-24 given a sales recovery, normalizing delivery, and improving homebuyer confidence. We believe earnings have bottomed especially as the one-off write-downs of inventories and jointly developed projects and foreign exchange losses in 2022 are unlikely to be repeated in 2023 and are non-cash flow items. We foresee that COLI will post a meaningful 22.4% EPS growth in 2023 off a low base. We also like the countercyclical landbank acquisition by COLI with 85% of land premium allocated to higher-tier cities in 2022. That said, we are slightly more conservative on our long-run gross margin assumptions due to heightened land cost, which leads to a mild reduction in our fair value estimate to HKD 29 from HKD 30. At our valuation, COLI is trading at around 0.8 times price/book, a reasonable level compared with 0.5-1.2 times in 2019-21. Also, we think long-term investors will find COLI attractive at the current share price level at its 5%-6% dividend yield.
Despite a 16% year-on-year dip in contracted sales (excluding associates and joint ventures) in 2022, COLI has posted a swift rebound of over 70% year on year in January to February 2023 thanks to a stronghold in higher-tier cities. In 2022, COLI added CNY 186.2 billion to salable resources with 87% in Tier 1 and Tier 2 cities. We believe this bodes well for continuing sales recovery and expect a 21% uptick in contracted sales for 2023. Looking into the next few years, competition over high-quality land parcels will remain intense, which pressures COLI’s scaling pace. However, we think COLI is well positioned to post a double-digit land premium growth in 2023 given its strong financial position. We expect income from associates and joint ventures to gradually improve given their exposure to lower-tier cities.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.